Fulcrum Therapeutics Inc
Research Fulcrum Therapeutics Inc (FULC) on Bullrun: market cap USD 294.46M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerFULC
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 294.46M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 26.18M
- Free cash flow-USD 16.15M
Valuation Snapshot
latest market cap is USD 294.46M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 74.88M | -USD 60.38M | n/a | -1.18 | USD 197.53M | USD 6.44M | USD 349.00M |
| FY2024 | USD 80.00M | -USD 9.73M | -USD 2.50M | n/a | -0.16 | USD 58.21M | USD 8.63M | USD 243.03M |
| FY2023 | USD 2.81M | -USD 97.34M | -USD 91.47M | n/a | -1.59 | USD 25.56M | USD 10.82M | USD 235.19M |
| FY2022 | USD 6.34M | -USD 109.87M | -USD 99.01M | n/a | -2.44 | USD 35.10M | USD 14.64M | USD 198.94M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 294.46M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 753.01M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 253.65M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 417.30M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 378.93M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 718.68M | n/a | n/a | n/a |
About Fulcrum Therapeutics Inc
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Fulcrum Therapeutics Inc's market cap?
Fulcrum Therapeutics Inc's market capitalization is USD 294.46M.
What does Fulcrum Therapeutics Inc do?
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders.